《中国非小细胞肺癌MET免疫组化检测与解读标准专家共识（2023年版）》 - Suppr | 超能文献

[Chinese expert consensus on MET immunohistochemistry detection and interpretation standards for non-small cell lung cancer(2023 version)].

出版信息

Zhonghua Bing Li Xue Za Zhi. 2023 Nov 8;52(11):1090-1097. doi: 10.3760/cma.j.cn112151-20230626-00423.

DOI:10.3760/cma.j.cn112151-20230626-00423

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

[Chinese expert consensus on MET immunohistochemistry detection and interpretation standards for non-small cell lung cancer(2023 version)].《中国非小细胞肺癌MET免疫组化检测与解读标准专家共识（2023年版）》

Zhonghua Bing Li Xue Za Zhi. 2023 Nov 8;52(11):1090-1097. doi: 10.3760/cma.j.cn112151-20230626-00423.

2

Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations.非小细胞肺癌中外显子14跳跃突变：生物学、临床结局及检测考量概述

JCO Precis Oncol. 2021 Apr 13;5. doi: 10.1200/PO.20.00516. eCollection 2021.

3

[Expert consensus on clinical practice of RET fusion detection in non-small cell lung cancer in China].《中国非小细胞肺癌RET融合检测临床实践专家共识》

Zhonghua Bing Li Xue Za Zhi. 2021 Jun 8;50(6):583-591. doi: 10.3760/cma.j.cn112151-20210411-00273.

4

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.MET 改变的非小细胞肺癌诊断与治疗专家共识

Cancer Biol Med. 2025 Apr 8;22(3):237-65. doi: 10.20892/j.issn.2095-3941.2024.0503.

5

[Expert Consensus on Diagnosis and Treatment of NSCLC with MET Abnormalities  (2025 Version)].《非小细胞肺癌伴MET异常诊治专家共识（2025年版）》

Zhongguo Fei Ai Za Zhi. 2025 Feb 20;28(2):81-94. doi: 10.3779/j.issn.1009-3419.2025.102.01.

6

MET Immunohistochemistry Should Be Avoided in Selecting Non-small-cell Lung Cancers Requiring MET Exon 14 Skipping Mutation Analysis.在选择需要进行MET外显子14跳跃突变分析的非小细胞肺癌时，应避免使用MET免疫组织化学检测。

Clin Lung Cancer. 2019 May;20(3):e418-e420. doi: 10.1016/j.cllc.2018.12.002. Epub 2018 Dec 12.

7

A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.在东亚人群中，与其他驱动基因突变相比，对携带 MET 外显子 14 跳跃突变的肺癌患者的临床结局进行全面分析。

Lung Cancer. 2017 Jan;103:82-89. doi: 10.1016/j.lungcan.2016.12.001. Epub 2016 Dec 5.

8

[Expert consensus on clinical practice of fusion genes detection in non-small cell lung cancer in China (2023 version)].中国非小细胞肺癌融合基因检测临床实践专家共识（2023年版）

Zhonghua Bing Li Xue Za Zhi. 2023 Jun 8;52(6):565-573. doi: 10.3760/cma.j.cn112151-20221111-00946.

9

MET: a new promising biomarker in non-small-cell lung carcinoma.MET：非小细胞肺癌中一种新的有前景的生物标志物。

Pharmacogenomics. 2015;16(6):631-47. doi: 10.2217/pgs.15.11. Epub 2015 Apr 20.

10

Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.非小细胞肺癌中 ALK、MET 和 ROS1 改变的平行筛查及其对日常常规检测的影响。

Lung Cancer. 2015 Feb;87(2):122-9. doi: 10.1016/j.lungcan.2014.11.018. Epub 2014 Dec 6.

引用本文的文献

1

[Expert Consensus on Diagnosis and Treatment of NSCLC with MET Abnormalities  (2025 Version)].《非小细胞肺癌伴MET异常诊治专家共识（2025年版）》

Zhongguo Fei Ai Za Zhi. 2025 Feb 20;28(2):81-94. doi: 10.3779/j.issn.1009-3419.2025.102.01.

2

Landscape of C-MET overexpression in non-small cell lung cancer: a large-scale study of clinicomolecular features and prognosis based on Chinese data.非小细胞肺癌中C-MET过表达情况：基于中国数据的临床分子特征及预后的大规模研究

Ther Adv Med Oncol. 2024 Sep 25;16:17588359241279715. doi: 10.1177/17588359241279715. eCollection 2024.

3

MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature.实体瘤中MET改变的检测平台及其临床意义：文献综述

Ther Adv Med Oncol. 2024 Jan 18;16:17588359231221910. doi: 10.1177/17588359231221910. eCollection 2024.